In this video, Dr. Matthew Krebs, Clinical Senior Lecturer in Experimental Cancer Medicine at the University of Manchester, shares his thoughts on the potential of EP0031 in transforming the landscape of RET-altered cancer treatment. With preliminary data showcasing encouraging efficacy and safety outcomes from a cohort of 109 patients, EP0031 presents hope for patients facing this challenging diagnosis.